Masafumi Ikeda

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

L. Bartalini, Margherita Rimini, Masafumi Ikeda, Oluseyi Abidoye et autres

it, jp, us, kr, ca, de, es, be, gb, au, ps, pt, at, tw, hk, cn (code pays fourni par la source)

Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102

Yasutoshi Kuboki, Takafumi Koyama, Masafumi Ikeda, Tomoyuki Satake et autres

jp, us, sg, ch (code pays fourni par la source)

Consensus on standardized later-line systemic therapy for hepatocellular carcinoma

Hongli Yu, Jiamin Cheng, Feng Xia, Stephen L. Chan et autres

cn, hk, il, kr, mn, jp, Égypte, sg (code pays fourni par la source)

Clinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc Analysis

Eric K. Rowinsky, Ghassan K. Abou‐Alfa, Junji Furuse, Makoto Ueno et autres

us, ie, jp (code pays fourni par la source)

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study

Do‐Youn Oh, Masafumi Ikeda, Teresa Macarulla, Aiwu Ruth He et autres

kr, jp, es, us, it, de, sg, fr, ca (code pays fourni par la source)

Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis

Silvia Camera, A. Vogel, M. Rimini, Masafumi Ikeda et autres

it, ca, jp, us, kr, de, be, gb, pt, es, at, tw, hk, cn (code pays fourni par la source)

58Beacon-BTC: A Phase 3 Randomized Study Evaluating Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer

Eric K. Rowinsky, Ghassan K. Abou‐Alfa, Masafumi Ikeda, Makoto Ueno et autres

us, jp (code pays fourni par la source)

Abstract 1083: Kras activity-linked glycolysis and immunosuppression in metastatic pancreatic cancer

Shuichi Mitsunaga, Mari Masuda, Kota Kato, Hidetaka Suzuki et autres

jp, gb (code pays fourni par la source)

Homologous Recombination Deficiency as a Biomarker for Chemoimmunotherapy Benefit in Advanced Biliary Tract Cancer: A Multicenter Retrospective Cohort Study

Oluseyi Abidoye, Heidi Kosiorek, Taro Shibuki, Angelo Pirozzi et autres

us, jp, br (code pays fourni par la source)

Change in Liver Function after Selective Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: JIVROSG-2001 PRESIDENT-ALBI – A Secondary Analysis of a Multicenter Randomized Controlled Trial

Yoshihisa Kodama, Masafumi Ikeda, Yasuaki Arai, Yoshitaka Inaba et autres

jp, us (code pays fourni par la source)

Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Alka A. Potdar et autres

Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Alka A. Potdar et autres